Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

Getting an Accurate Diagnosis

At a Glance

Infundibulo-neurohypophysitis is diagnosed by combining pituitary MRI with hormone testing, especially stimulated copeptin testing or supervised water deprivation. Because imaging can mimic tumors and infections, doctors may monitor stable cases and reserve biopsy for atypical or worsening lesions.

Diagnosing infundibulo-neurohypophysitis (INH) is a complex puzzle because the pituitary stalk can become inflamed or thickened for many different reasons. Because an incorrect diagnosis could lead to unnecessary surgery or missed cancer, doctors use a combination of advanced imaging, hormone “stress tests,” and a rigorous process of ruling out “look-alike” conditions [1][2].

The MRI: Looking for Clues

A dedicated, contrast-enhanced MRI of the sella turcica (the bony pocket holding the pituitary) is the first step. Two specific findings are common in INH:

  • Pituitary Stalk Thickening: The stalk (infundibulum) typically looks wider than normal. In some cases, doctors use a threshold of 6.5–7 mm as a point where they become more concerned about tumors, though this is not a universal decision rule and must be weighed against other clinical factors [3][2].
  • Loss of the “Bright Spot”: In a healthy person, the back of the pituitary gland (the neurohypophysis) shows up as a bright white spot on certain MRI sequences (T1-weighted). In INH, this bright spot often disappears because the gland is not storing vasopressin properly [4][5].

Importantly, these signs are nonspecific. They show that something is wrong with the posterior pituitary, but they cannot prove that the cause is autoimmune inflammation, and an absent bright spot can occur in healthy people as well [6].

Confirming AVP-D: Hormone Testing

To prove your body isn’t making enough vasopressin, doctors perform a stimulation test.

  • The Stimulated Copeptin Test: This is an increasingly useful diagnostic tool in expert centers [7]. You are given a concentrated salt solution (saline) through an IV to safely raise your blood sodium levels, and doctors measure copeptin, a protein released alongside vasopressin. A low result supports a diagnosis of Arginine Vasopressin Deficiency (AVP-D). However, it requires a controlled protocol, close sodium monitoring, and specialist interpretation, and partial AVP-D can produce indeterminate results [7][8].
  • Water Deprivation Test: The older standard, where you stop drinking for many hours under medical supervision, remains an accepted alternative where appropriate [8][9].

The “Look-Alikes”: Ruling Out Other Causes

Before a diagnosis of INH is made, your care team must rule out several other conditions that can cause a thickened pituitary stalk [10]. Even if tumor markers in the blood or spinal fluid are normal, a multidisciplinary team will evaluate the differential diagnosis:

  • Tumors: Such as germinomas (common in children/young adults) or metastasis (cancer spread from elsewhere) [2][11].
  • Infiltrative Diseases: Conditions where abnormal cells invade the tissue, such as Langerhans Cell Histiocytosis (LCH), Erdheim-Chester Disease, or Sarcoidosis [2][12].
  • IgG4-Related Disease: A systemic disorder involving characteristic tissue infiltration by IgG4-positive plasma cells and fibrosis, requiring clinical, imaging, and often tissue correlation to diagnose [10].
  • Infections: Such as tuberculosis or syphilis, though these are rarer [10].

The Pituitary Stalk Biopsy: Benefits and Risks

A biopsy—taking a small tissue sample from the stalk—can provide a tissue diagnosis. However, it is a high-risk procedure usually reserved by a multidisciplinary team for cases where the MRI shows the lesion is growing, atypical, or highly symptomatic [13][14].

Potential Benefit Serious Risks
Tissue Diagnosis: Can help confirm or rule out cancer/tumors, though a systematic review found diagnostic yields around 95.8%, meaning sampling limitations occasionally occur [15]. Permanent Hormone Loss: The same systematic review reported that approximately 15.7% of patients developed new, permanent hypopituitarism (multiple anterior pituitary deficiencies) [15].
Tailored Treatment: Ensures you receive the right medication (e.g., steroids for inflammation vs. chemo for a tumor). New AVP-D: Roughly 9.0% of patients who didn’t have it before developed permanent AVP-D after the biopsy [15].
Peace of Mind: Resolves the uncertainty of “watchful waiting.” Other Risks: General risks include meningitis (2.7%), vision changes (1.6%), or CSF leaks (1.6%), though center-specific rates vary [15].

In many cases, if the symptoms are stable, doctors choose “watchful waiting” with repeat MRIs every 3–6 months to see if the inflammation shrinks on its own, which is a common trait of autoimmune INH [3][16].

Common questions in this guide

What MRI findings can suggest infundibulo-neurohypophysitis?
A contrast-enhanced MRI of the pituitary may show a thickened pituitary stalk or loss of the normal bright spot in the back of the gland. These findings are not specific to INH, and an absent bright spot can also be seen in healthy people, so MRI alone cannot confirm the diagnosis.
How do doctors test for arginine vasopressin deficiency in suspected INH?
A stimulated copeptin test uses a carefully monitored saline infusion to raise blood sodium and measure copeptin, which is released with vasopressin. A low result supports arginine vasopressin deficiency (AVP-D), but partial deficiency can give unclear results; a supervised water-deprivation test is another accepted option.
What other conditions can look like INH on scans?
A thickened pituitary stalk can also occur with tumors such as germinoma or cancer spread, infiltrative diseases such as Langerhans cell histiocytosis, Erdheim-Chester disease, or sarcoidosis, and IgG4-related disease. Doctors may also test for infections such as tuberculosis or syphilis before accepting INH as the explanation.
What does a pituitary stalk measurement of 6.5–7 mm mean?
A stalk measuring about 6.5–7 mm may make doctors more concerned about a tumor, but it is not a universal rule or a diagnosis by itself. Symptoms, the full MRI appearance, hormone results, and changes over time all help determine the next step.
Does everyone with suspected INH need a pituitary stalk biopsy?
No, not everyone needs a biopsy. It is usually considered when the lesion is growing, looks atypical on imaging, or causes significant symptoms, while stable cases may be followed with repeat MRI every 3–6 months.
What are the risks of a pituitary stalk biopsy?
A biopsy can provide a tissue diagnosis, but it may cause permanent loss of pituitary hormones or new arginine vasopressin deficiency. Other reported risks include meningitis, vision changes, and cerebrospinal-fluid leakage, and rates vary by medical center.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Infundibulo-neurohypophysitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does the diameter of my pituitary stalk (specifically if it is near or above 6.5–7 mm) make a biopsy more necessary?
  2. 2.Why was the copeptin test or water deprivation test chosen for my diagnosis, and how clear were the results?
  3. 3.What specific tumor markers (like beta-hCG or AFP) or systemic tests have you used to rule out mimics like germinoma or sarcoidosis?
  4. 4.What is your team's specific experience with pituitary stalk biopsies, and what are your personal rates for post-surgical hormone loss?
  5. 5.If we choose 'watchful waiting' with serial MRIs, what specific changes in the scan or my symptoms would trigger an immediate biopsy?

References

References (16)
  1. 1

    Lymphocytic infundibulo-neurohypophysitis: a clinical overview.

    Johnston PC, Chew LS, Hamrahian AH, Kennedy L

    Endocrine 2015; (50(3)):531-6 doi:10.1007/s12020-015-0707-6.

    PMID: 26219407
  2. 2

    Pituitary stalk thickening in patients under 18 years of age - the most common causes and diagnostic procedures.

    Moszczyńska E, Baszyńska-Wilk M, Zasada K, et al.

    Pediatric endocrinology, diabetes, and metabolism 2022; (28(3)):213-227 doi:10.5114/pedm.2022.115202.

    PMID: 35620922
  3. 3

    Clinical presentation and outcome of children with central diabetes insipidus associated with a self-limited or transient pituitary stalk thickening, diagnosed as infundibuloneurohypophysitis.

    Schaefers J, Cools M, De Waele K, et al.

    Clinical endocrinology 2017; (87(2)):171-176 doi:10.1111/cen.13362.

    PMID: 28444954
  4. 4

    A Case of Lymphocytic Infundibulo-neurohypophysitis Exhibiting Spontaneous Regression.

    Hasebe M, Shibue K, Honjo S, Hamasaki A

    JCEM case reports 2023; (1(2)):luad020 doi:10.1210/jcemcr/luad020.

    PMID: 37908468
  5. 5

    Lymphocytic infundibuloneurohypophysitis with positive anti-rabphilin-3A antibodies nine years post-onset of central diabetes insipidus.

    Kume Y, Sakuma H, Sekine H, et al.

    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2021; (30(1)):65-69 doi:10.1297/cpe.30.65.

    PMID: 33446956
  6. 6

    Infantile-Onset Isolated Neurohypophyseal Langerhans Cell Histiocytosis with Central Diabetes Insipidus: A Case Report.

    Tani M, Hiroshima S, Sato H, et al.

    Children (Basel, Switzerland) 2022; (9(5)) doi:10.3390/children9050716.

    PMID: 35626895
  7. 7

    Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency.

    Refardt J, Atila C, Chifu I, et al.

    The New England journal of medicine 2023; (389(20)):1877-1887 doi:10.1056/NEJMoa2306263.

    PMID: 37966286
  8. 8

    A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.

    Fenske W, Refardt J, Chifu I, et al.

    The New England journal of medicine 2018; (379(5)):428-439 doi:10.1056/NEJMoa1803760.

    PMID: 30067922
  9. 9

    Copeptin in the differential diagnosis of hypotonic polyuria.

    Christ-Crain M, Fenske WK

    Journal of endocrinological investigation 2020; (43(1)):21-30 doi:10.1007/s40618-019-01087-6.

    PMID: 31368050
  10. 10

    Pituitary Stalk Enlargement in Adults.

    Hána V, Salenave S, Chanson P

    Neuroendocrinology 2020; (110(9-10)):809-821 doi:10.1159/000506641.

    PMID: 32074610
  11. 11

    Central diabetes insipidus caused by a pituitary stalk germinoma resembling infundibuloneurohypophysitis.

    Dias D, Vilar H, Passos J, Leite V

    BMJ case reports 2020; (13(9)) doi:10.1136/bcr-2020-234724.

    PMID: 32912882
  12. 12

    Clinical and radiological insights into secondary hypophysitis: A single-center experience with a focus on tuberculosis.

    Rao A, Lila AR, Karlekar M, et al.

    Endocrine 2025; (90(1)):266-275 doi:10.1007/s12020-025-04352-2.

    PMID: 40627285
  13. 13

    Etiological Spectrum and Pattern of Change in Pituitary Stalk Thickening: Experience in 321 Patients.

    Zhou X, Zhu H, Yao Y, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(8)):3419-3427 doi:10.1210/jc.2018-02297.

    PMID: 30892632
  14. 14

    Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline.

    Cerbone M, Visser J, Bulwer C, et al.

    The Lancet. Child & adolescent health 2021; (5(9)):662-676 doi:10.1016/S2352-4642(21)00088-2.

    PMID: 34214482
  15. 15

    Pituitary stalk biopsy - A systematic review of the safety and efficacy of stalk lesion biopsy.

    Dolovac RB, McCormack A, Evans LR, et al.

    Pituitary 2026; (29(3)).

    PMID: 42050282
  16. 16

    A 4-year-old Boy Positive for Anti-rabphilin-3A Antibody and Diagnosed With Lymphocytic Infundibuloneurohypophysitis.

    Yamamoto A, Komatsu N, Iwata N, et al.

    JCEM case reports 2025; (3(1)):luae214 doi:10.1210/jcemcr/luae214.

    PMID: 39726668

This page explains INH diagnosis for informational purposes only and does not constitute medical advice. Your medical team should interpret your MRI, hormone tests, and biopsy options in the context of your individual situation.